ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $85 from $98 and keeps a Buy rating on the shares.

CRISPR Therapeutics (CRSP) proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company’s annual general meeting to be ...

Analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued on Monday, January 6th. Brookline Capital Management ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that ...

The most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $39.36, reflecting a +1.84% shift from the previouse trading day's closing. The stock exceeded the S&P 500 ...